Vaccine 32 (2014) 2127–2133
Contents lists available at ScienceDirect
Vaccine journal homepage: www.elsevier.com/locate/vaccine
Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women Stephen C. Ko a,∗ , Sarah F. Schillie a , Tanja Walker a , Steven L. Veselsky a , Noele P. Nelson a , Julie Lazaroff b , Susan Crowley c , Cristina Dusek d , Khalilah Loggins e , Kenneth Onye f , Nancy Fenlon g , Trudy V. Murphy a a Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, United States b New York City Department of Health and Mental Hygiene, New York, NY, United States c Minnesota Department of Health, Saint Paul, MN, United States d Florida Department of Health, Tallahassee, FL, United States e Texas Department of State Health Services, Austin, TX, United States f Michigan Department of Community Health, Lansing, MI, United States g Immunization Services Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, United States
a r t i c l e
i n f o
Article history: Received 13 November 2013 Received in revised form 14 January 2014 Accepted 30 January 2014 Available online 22 February 2014 Keywords: Hepatitis B Antibody response Perinatal Vaccine Immunization
a b s t r a c t Purpose: Annually, an estimated 25,000 infants are born to hepatitis B surface antigen (HBsAg)-positive women in the United States. Hepatitis B (HepB) vaccine and hepatitis B immune globulin (HBIG) are recommended at birth, followed by completion of vaccine series and post-vaccination serologic testing (PVST). In a large cohort of infants born to HBsAg-positive women, factors influencing vaccine response were evaluated. Methods: Data were from HBsAg-negative infants born to HBsAg-positive women in the Enhanced Perinatal Hepatitis B Prevention Program (EPHBPP) from 2008 to 2013. Vaccine non-responders were defined as infants with antibody to hepatitis B surface antigen (anti-HBs)
Contents lists available at ScienceDirect
Vaccine journal homepage: www.elsevier.com/locate/vaccine
Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women Stephen C. Ko a,∗ , Sarah F. Schillie a , Tanja Walker a , Steven L. Veselsky a , Noele P. Nelson a , Julie Lazaroff b , Susan Crowley c , Cristina Dusek d , Khalilah Loggins e , Kenneth Onye f , Nancy Fenlon g , Trudy V. Murphy a a Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, United States b New York City Department of Health and Mental Hygiene, New York, NY, United States c Minnesota Department of Health, Saint Paul, MN, United States d Florida Department of Health, Tallahassee, FL, United States e Texas Department of State Health Services, Austin, TX, United States f Michigan Department of Community Health, Lansing, MI, United States g Immunization Services Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, United States
a r t i c l e
i n f o
Article history: Received 13 November 2013 Received in revised form 14 January 2014 Accepted 30 January 2014 Available online 22 February 2014 Keywords: Hepatitis B Antibody response Perinatal Vaccine Immunization
a b s t r a c t Purpose: Annually, an estimated 25,000 infants are born to hepatitis B surface antigen (HBsAg)-positive women in the United States. Hepatitis B (HepB) vaccine and hepatitis B immune globulin (HBIG) are recommended at birth, followed by completion of vaccine series and post-vaccination serologic testing (PVST). In a large cohort of infants born to HBsAg-positive women, factors influencing vaccine response were evaluated. Methods: Data were from HBsAg-negative infants born to HBsAg-positive women in the Enhanced Perinatal Hepatitis B Prevention Program (EPHBPP) from 2008 to 2013. Vaccine non-responders were defined as infants with antibody to hepatitis B surface antigen (anti-HBs)
